The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) is hosting a virtual patient-focused drug development listening meeting to better understand patient perspectives on gene therapy products, including cell-mediated gene therapy.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/oXtAv7J
No comments:
Post a Comment